Investigation By UK Competition Authority ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa)(“Aspen Holdings”) Registration number 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen”) INVESTIGATION BY UK COMPETITION AUTHORITY Shareholders are advised that the the UK Competition and Markets Authority (“CMA”) has opened an investigation against Aspen into alleged anti-competitive conduct in relation to the supply of Fludrocortisone acetate 0.1 mg tablets and Dexamethasone 2 mg tablets in the UK. In 2016 the two products had a combined revenue of GBP11.1 million in the UK. The investigation is at an early, information-gathering stage and the CMA has confirmed that, at this time, it has not reached any conclusion on whether competition law has been infringed. While Aspen is not currently in a position to comment on this investigation, it reaffirms its commitment to fair and open competition in the UK and around the world. Aspen takes compliance with competition laws very seriously and will work constructively with the CMA in its process. Shareholders are advised that any material developments in these proceedings will be communicated through SENS. Shareholders should exercise care when reacting to information on this matter which has not been released by Aspen Holdings. Durban 13 October 2017 Sponsor: Investec Bank Limited About Aspen Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to its high quality affordable medicines and products. As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential. Aspen has a strong presence in both emerging and developed countries with more than 60 established business operations in approximately 50 countries. Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are scaleable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals. Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies on this exchange. For more information visit: http://www.aspenpharma.com/ Date: 13/10/2017 05:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.